Patents by Inventor Ling Ding

Ling Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6841234
    Abstract: Heat-activated adhesive tape has a backing comprising 88-92% acrylic polymer containing: 35-45% of a first alkyl acrylate monomer with alkyl groups containing 4 to 12 carbon atoms, 30-40% of a second alkyl acrylate monomer with alkyl groups containing 4 to 12 carbon atoms, 6-10% a first monoethylenically unsaturated polar copolymerizable monomer, 1-2% a second monoethylenically unsaturated polar copolymerizable monomer, 0.3-0.5% photoinitiator, 1-2% filler, 0.05-0.07% crosslinker/chain extender, and 8-12% hollow glass microspheres; and heat-activated adhesive layer on at least one side. A pressure-sensitive adhesive may be on the other side.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: January 11, 2005
    Assignee: Scapa Tapes North America Inc.
    Inventors: Ramesh Lhila, Kwang-Yol Park, Kaila Delpozzo, Jian Ling Ding
  • Patent number: 6733997
    Abstract: A universal secretory signal originally derived from a piscine vitellogenin (Vtg) gene is inserted into various expression vectors for driving the secretion of the recombinant protein into the culture medium. This enhances the detection, quantification and downstream scaled-up purification of a recombinant protein of interest. The secretory signal system is very versatile, being conveniently and widely applicable to an array of heterologous host cells such as bacteria, yeast, insect, piscine, and mammalian cell lines (e.g., COS, CHO, NIH/3T3). The said secretory system is also applicable as a reporter vector for secretion of reporter proteins/enzymes, thus, enabling the detection of the reporter proteins (e.g., CAT, GFP) in the culture medium.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: May 11, 2004
    Assignee: National University of Singapore
    Inventors: Jeak Ling Ding, Nguan Soon Tan, Bow Ho, Toong Jin Lam
  • Patent number: 6645724
    Abstract: The horseshoe crab, Carcinoscorpius rotundicauda Factor C cDNA (CrFC21) has been cloned into a shuttle baculoviral vector and another vector suitable for expression in insect cells. The recombinant baculoviral DNA was then transfected into the insect cells for expression of recombinant Factor C. Recombinant Factor C was found to be immunoreactive and is capable of binding both free and bound/immobilized lipid A. It is enzymatically active when triggered by LPS. The rFC is probably of the two-chain form, being cleaved into the heavy and light chains after activation by Gram negative bacterial endotoxin. As low as 0.01 pg (0.001 ng/ml) of LPS was detectable by the rFC, thus, indicating its potentials as a novel generation of “limulus amoebocyte lysate.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: November 11, 2003
    Assignee: National University of Singapore
    Inventors: Jeak Ling Ding, Bow Ho
  • Publication number: 20030125680
    Abstract: A hydrocolloid bandage for the wound care designed for improved pliability and decreased peripheral edge lift. In particular, the invention is concerned with a hydrocolloid bandage which is absorbent, non-damaging to the skin and comfortable to the user preferably having at least a hydrocolloid region covered by film and adhesive layers which contact the user's skin at the periphery of the bandage.
    Type: Application
    Filed: December 31, 2002
    Publication date: July 3, 2003
    Inventor: Jian Ling Ding
  • Publication number: 20020147265
    Abstract: Hydrocolloid compositions are provided having improved advantages over previous hydrocolloid compositions. The novel hydrocolloid compositions herein disclosed are particularly useful in the manufacturing of dressings for application to the skin of a user for wound care, displaying improved integrity, absorption and adhesion. Methods of manufacturing the hydrocolloid compositions are also provided.
    Type: Application
    Filed: January 17, 2002
    Publication date: October 10, 2002
    Applicant: Scapa North America
    Inventors: Jian Ling Ding, Ferdinando J. D'Amato
  • Publication number: 20020106400
    Abstract: A calendered hydrocolloid dressing for the wound care and a one step method of manufacturing the hydrocolloidal dressing are described. In particular, the invention is concerned with a hydrocolloid dressing which is absorbent, non-damaging to the skin and comfortable to the user preferably having at least a thermoplastic elastomer backing and water absorbent polymeric adhesive layer.
    Type: Application
    Filed: August 8, 2001
    Publication date: August 8, 2002
    Inventors: Scott C. Barnes, Jing Ling Ding
  • Publication number: 20020028326
    Abstract: Heat-activated adhesive tape has a backing comprising 88-92% acrylic polymer containing: 35-45% of a first alkyl acrylate monomer with alkyl groups containing 4 to 12 carbon atoms, 30-40% of a second alkyl acrylate monomer with alkyl groups containing 4 to 12 carbon atoms, 6-10% a first monoethylenically unsaturated polar copolymerizable monomer, 1-2% a second monoethylenically unsaturated polar copolymerizable monomer, 0.3-0.5% photoinitiator, 1-2% filler, 0.05-0.07% crosslinker/chain extender, and 8-12% hollow glass microspheres; and heat-activated adhesive layer on at least one side. A pressure-sensitive adhesive may be on the other side.
    Type: Application
    Filed: August 1, 2001
    Publication date: March 7, 2002
    Applicant: Scapa Tapes North America Inc.
    Inventors: Ramesh Lhila, Kwang-yol Park, Kaila Delpozzo, Jian Ling Ding
  • Patent number: 5985590
    Abstract: CrFC21 cDNA was cloned into two mammalian vectors: pCIneo and pCDNAI, both of which carry the strong CMV promoter for expression in mammalian cell lines. Various CrFC cDNA constructs transformed into P. pastoris and S. cerevisiae were expressed to yield full-length recombinant Factor C (rCrFC) protein of .about.130 kDa which is immunoreactive. The rCrFC is expressed in an intracellular, insoluble form. Intracellular localization of the nascent protein provides protection from premature digestion by proteases secreted by the host cell. Subsequent to its synthesis, rCrFC is solubilized and purified under pyrogen-free conditions. Using established protocols, the protein can be denatured and renatured to recover its biological functionality. By manipulation of the 5' end of CrFC26, truncated constructs containing this cDNA are expressed by S. cerevisiae to give immunoreactive rCrFC. The rCrFC produced from both CrFC21 and CrFC26 constructs, solubilized by Triton X-100 or SDS, is found to be immunoreactive.
    Type: Grant
    Filed: June 18, 1997
    Date of Patent: November 16, 1999
    Assignee: National University of Singapore
    Inventors: Jeak Ling Ding, Bow Ho
  • Patent number: 5858706
    Abstract: CrFC21 cDNA was cloned into two mammalian vectors: pCIneo and pCDNAI, both of which carry the strong CMV promoter for expression in mammalian cell lines. Various CrFC cDNA constructs transformed into P. pastoris and S. cerevisiae were expressed to yield full-length recombinant Factor C (rCrFC) protein of .about.130 kDa which is immunoreactive. The rCrFC is expressed in an intracellular, insoluble form. Intracellular localization of the nascent protein provides protection from premature digestion by proteases secreted by the host cell. Subsequent to its synthesis, rCrFC is solubilized and purified under pyrogen-free conditions. Using established protocols, the protein can be denatured and renatured to recover its biological functionality. By manipulation of the 5' end of CrFC26, truncated constructs containing this cDNA are expressed by S. cerevisiae to give immunoreactive rCrFC. The rCrFC produced from both CrFC21 and CrFC26 constructs, solubilized by Triton X-100 or SDS, is found to be immunoreactive.
    Type: Grant
    Filed: February 2, 1996
    Date of Patent: January 12, 1999
    Assignee: National University of Singapore
    Inventors: Jeak Ling Ding, Bow Ho
  • Patent number: 5716834
    Abstract: Full-length and deletion subclones of cDNAs for Factor C of Carcinoscorpius rotundicauda are provided. These cDNAs have been cloned into .lambda.gt 22 and pGEM 11Zf(+). Further manipulations of the 5' and 3' ends of these cDNAs have been carried out, and these cDNAs have been further subcloned into other expression vectors such as pGEMEX-1, pET 3b, and the yeast shuttle vectors YEpsec 1 and pEMBLyex 4, and pPIC 9 and pHIL D2. Also provided are host cells transformed with expression vectors containing DNA molecules encoding proteins having Factor C-like enzymatic activity, methods of producing such proteins, methods for purifying Factor C zymogens, and methods for protecting Factor C zymogens from autoactivation by Gram negative bacterial endotoxin while the proenzyme is being purified and/or processed from amoebocyte lysates or from recombinant clones, or during storage or subsequent handling. This protection is afforded by the addition of 5-30% Me.sub.2 SO, which reversibly inhibits the Factor C zymogen.
    Type: Grant
    Filed: August 19, 1994
    Date of Patent: February 10, 1998
    Assignee: National University of Singapore
    Inventors: Jeak Ling Ding, Bow Ho
  • Patent number: 5712144
    Abstract: Full-length and deletion subclones of cDNAs for Factor C of Carcinoscorpius rotundicauda are provided. These cDNAs have been cloned into .lambda.gt 22 and pGEM 11Zf(+). Further manipulations of the 5' and 3' ends of these cDNAs have been carried out, and these cDNAs have been further subcloned into other expression vectors such as pGEMEX-1, pET 3b, and the yeast shuttle vectors YEpsec 1 and pEMBLyex 4, and pPIC 9 and pHIL D2. Also provided are host cells transformed with expression vectors containing DNA molecules encoding proteins having Factor C-like enzymatic activity, methods of producing such proteins, methods for purifying Factor C zymogens, and methods for protecting Factor C zymogens from autoactivation by Gram negative bacterial endotoxin while the proenzyme is being purified and/or processed from amoebocyte lysates or from recombinant clones, or during storage or subsequent handling. This protection is afforded by the addition of 5-30% Me.sub.2 SO, which reversibly inhibits the Factor C zymogen.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 27, 1998
    Assignee: National University of Singapore
    Inventors: Jeak Ling Ding, Bow Ho